Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.42, Bloomberg Earnings reports. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company had revenue of $186.78 million during the quarter, compared to the consensus estimate of $192.45 million. During the same quarter in the previous year, the firm earned $0.40 earnings per share. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Omnicell updated its Q4 guidance to $0.49-0.55 EPS.
Omnicell (NASDAQ OMCL) opened at $46.40 on Monday. Omnicell has a one year low of $31.50 and a one year high of $55.40. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53.
COPYRIGHT VIOLATION WARNING: “Omnicell, Inc. (OMCL) Issues Earnings Results” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/13/omnicell-inc-omcl-releases-earnings-results-hits-estimates.html.
OMCL has been the subject of several recent analyst reports. Dougherty & Co boosted their price objective on shares of Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Craig Hallum boosted their price objective on shares of Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Cantor Fitzgerald reiterated a “buy” rating and issued a $47.00 price objective on shares of Omnicell in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research report on Thursday, October 19th. Finally, Benchmark Co. boosted their price objective on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. Omnicell has an average rating of “Buy” and a consensus price target of $54.86.
In other Omnicell news, VP Jorge R. Taborga sold 6,295 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $48.69, for a total value of $306,503.55. Following the completion of the sale, the vice president now owns 50,013 shares of the company’s stock, valued at $2,435,132.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter J. Kuipers sold 3,532 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $50.96, for a total transaction of $179,990.72. Following the completion of the sale, the vice president now directly owns 40,714 shares of the company’s stock, valued at approximately $2,074,785.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,741 shares of company stock valued at $3,139,399. Corporate insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.